title: Pembrolizumab (Keytruda) for metastatic melanoma.
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology*; D009362:Neoplasm Metastasis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab